Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,582.25
(
-0.64%
)
US TECH 100
23,609.20
(
-0.79%
)
Dow Jones
45,870.99
(
-0.77%
)
Brent Oil
104.34
(
-2.11%
)
Bitcoin
69,782.15
(
-2.05%
)
News Focus
News Focus
Post# of 257259
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122799
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: lgonber post# 193963

Friday, 07/31/2015 11:02:09 AM

Friday, July 31, 2015 11:02:09 AM

Post# of 257259
OXGN—To reiterate, I haven’t followed the company closely for several years. However, I do disagree with your contention that fosbretabulin (f/k/a CA4P) has a benign side-effect profile. Also, I would question any notion that the planned phase-3 trial in ovarian cancer is “lay down.” Regards, Dew

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now